Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer

Supportive Care in Cancer

Volumn 6, Issue 6, 1998, Pages 524-528

  Castagnola, Elio ^a   Paola, Dimitri ^a   Giacchino, Raffaella ^a   Rossi, Rossella ^a   Viscoli, Claudio ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Economic evaluation; Empiric antibiotic therapy; Febrile neutropenia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; CHILDHOOD CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CHILD; COSTS AND COST ANALYSIS; HUMANS; ITALY; NEOPLASMS; NEUTROPENIA;

EID: 0031797848     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050208     Document Type: Article

References (34)

1. Anonymous (1992) Carbapenems. In: Lambert HP, O'Grady FW (eds) Antibiotic and chemotherapy. Churchill Livingstone, London, pp 74-77
2. Anonymous (1992) Beta-lactamases. In: Lambert HP, O'Grady FW (eds) Antibiotic and chemotherapy. Churchill Livingstone, London, pp 80-83
3. Bodey GP (1993) Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 17 [Suppl 2]:S378-S384
4. Castagnola E, Giacchino M, Cesaro S, et al (1996) Resistance patterns among bacteremia isolates in italian pediatric cancer centers (abstract). J Clin Microbiol Infect 3 [Suppl 2]:332
5. Charnas R, Luethi Ridolfi A, Ruch W (1997) Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 16:346-353
6. Chow JW, Fine MJ, Shlaes DM, et al (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115:585-590
7. Cometta A, Glauser MP (1996) The use of aminoglycosides in neutropenic patients. Schweiz Med Wochenschr 126 [Suppl 76]:S21-S27
8. Cometta A, Zinner S, de Bock R, et al (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric theraphy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39:445-452
9. Cometta A, Calandra T, Gaya H, et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric theraphy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108-1115
10. Cordonnier C, Herbrecht R, Pico JL, et al (1997) Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 24:41-51
11. Davey P, Malek M, Parker S (1992) Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics 6:409-437
12. Del Favero A, Menichetti F, Guerciolini R, et al (1987) Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile granulocytopenic acute leukemia patients. Antimicrob Agents Chemother 31:1126-1129
13. Dejace P, Klastersky J (1986) Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med 80 [Suppl B]:29-38
14. De Pauw BE, Deresinski SC, Feld R, et al (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric theraphy for fever in neutropenic patients with cancer. Ann Intern Med 120:834-844
15. EORTC: International Antimicrobial Theraphy Cooperative Group (1993) Efficacy and toxicity of single daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593
16. EORTC: International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958
17. Fletcher CV, Metzler D, Borchardt-Phelps P, Rodman JH (1990) Patterns of antibiotics use and expenditures during 7 years at a university hospital. Pharmacotherapy 10:199-204
18. Foran RM, Judy LB, Wulf PH (1991) Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP Ann Pharmacother 25:546-551
19. Freifeld AG, Walsh T, Marshall D, et al (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
20. Hatala R, Dinh T, Cook DJ (1996) Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124:717-725
21. Herbrecht R, Blaise D, Espinouse D, et al (1995) Isepamicin once daily plus ceftriaxone in febrile neutropenic patients. J Chemother 7 [Suppl 2]: 103-110
22. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, et al (1991) Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 35:873-878
23. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ (1993) Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporin. Ann Intern Med 119:353-358
24. Micozzi A, Nucci N, Venditti N, et al (1993) Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 12:1-8
25. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332
26. Pizzo PA, Hathorn JW, Hiemenz J, et al (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558
27. Ramphal R, Gucalp R, Rotstein C, et al (1996) Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patients. Am J Med 100 [Suppl 6A]:83-89
28. Torfs K (1997) Economic evaluation of cancer treatment strategies. Eur J Cancer 33 [Suppl 4]:S35-S39
29. Viscoli C (1998) The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 41[Suppl D]:65-80
30. Viscoli C, Moroni C, Boni L, et al (1991) Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 13:397-404
31. Viscoli C, Bruzzi P, Glauser MP (1995) An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 31:2013-2022
32. Winston DJ, Winston G, Bruckner DA, et al (1991) Beta-Lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 115:849-859
33. Yamamura DH, Gucalp R, Carlisle P, Cimino M, Roberts J, Rostein C (1997) Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 41:1704-1708
34. Zinner SH (1997) Antimicrobial therapy in cancer patients: studies from the EORTC International Antimicrobial Therapy Cooperative Group. Eur J Cancer 33 [Suppl 4]:S44-S49